

from the dioxane/toluene reaction solution. Addition of P-EDC as a slurry in DMF solubilizes any precipitated urea intermediate.

Table 1. 2-Aminobenzoxazines **3**

Cmpd	R ₁	R ₂	Hplc purity (%) ^a	Yield (%) ^c
3a	4-methyl	Butyl	97	88
3b	4-methyl	Allyl	92	79
3c	4-methyl	2,6-diisopropylphenyl	87	93
3d	4-methyl	2-bromophenyl	88	90
3e	4-fluoro	Benzyl	96	89
3f	H	4-methoxyphenyl	95 ^b	82
3g	H	4-chlorophenyl	90 ^b	92
3h	2-chloro	Isopropyl	97	75
3i	2,4-dimethyl	4-isopropylphenyl	89	73
3j	2-methyl	2-ethylphenyl	89	86
3k	2-methoxy	2-chlorophenyl	85	75
3l	2-trifluoromethyl	2-methylphenyl	83	94
3m	4-iodo	Ethyl	80	81

^aPurity determined by hplc analysis of crude products. Products show satisfactory ¹H NMR or MS data. Side-products consist of symmetrical urea derived from the isocyanate.

^bCompared to authentic sample prepared by independent synthesis. ^cDetermined from weight of crude sample.

In conclusion, we have developed an easily automated solution-phase parallel synthesis of 2-aminobenzoxazines using anthranilic acids, isocyanates and P-EDC. This approach offers the potential of providing diverse libraries of benzoxazine derivatives for assay in biological systems.

REFERENCES AND NOTES

- (a) Nefzi, A.; Ostresh, J. M.; Houghten, R. A. *Chem. Rev.*, **1997**, *97*, 449-472. (b) Gallop, M. A.; Barrett, R. W.; Dower, W. J.; Fodor, S. P. A.; Gordon, E. M. *J. Med. Chem.* **1994**, *37*, 1233. (c) Gordon, E. M.; Gallop, M. A.; Barrett, R. W.; Dower, W. J.; Fodor, S. P. A. *J. Med. Chem.* **1994**, *37*, 1385.
- (a) Kaldor, S. W.; Siegel, M. G.; Fritz, J. E.; Dressman, B. A.; Hahn, P. J. *Tetrahedron Lett.* **1996**, *37*, 7193-7196. (b) Gayo, L. M.; Suto, M. J. *Tetrahedron Lett.* **1997**, *38*, 513-516. (c) Siegel, M. G.; Hahn, P. J.; Dressman, B. A.; Fritz, J. E.; Grunwell, J. R.; Kaldor, S. W. *Tetrahedron Lett.* **1997**, *19*, 3357-3360. (d) Thomas, J. B.; Fall, M. J.; Cooper, J. B.; Burgess, J. P.; Carroll, F. I., *Tetrahedron Lett.* **1997**, *38*, 5099-5102.
- Buckman, B. O.; Mohan, R. *Tetrahedron Lett.* **1996**, *26*, 4439-4442.
- (a) Krantz, A.; Spencer, R. W.; Tam, T. F.; Liak, T. J.; Copp, L. J.; Thomas, E. M.; Rafferty, S. P. *J. Med. Chem.* **1990**, *33*, 464-479. (b) Abood, N. A.; Schretzman, L. A.; Flynn, D. L.; Houseman, K. A.; Wittwer, A. J.; Dilworth, V. M.; Hippenmeyer, P. J.; Holwerda, B. C. *Bioorg. Med. Chem. Lett.* **1997**, *16*, 2105-2108. (c) Jarvest, R. L.; Parratt, M. J.; Debouck, C. M.; Gorniak, J. G.; Jennings, L. J.; Serafinowska, H. T.; Strickler, J. E. *Bioorg. Med. Chem. Lett.* **1996**, *20*, 2463-2466.
- Desai, M. C.; Stephens Stramiello, L. M. *Tetrahedron Lett.* **1993**, *48*, 7685-7688.
- Experimental Procedure: Using proprietary liquid handling equipment, anthranilic acid (110 μ L, 0.2 M in dioxane, 0.022 mmol, 1.1 equiv.) and p-methoxyphenyl isocyanate (100 μ L, 0.2 M in toluene, 0.020 mmol, 1.0 equiv.) are added to 250 μ L of dioxane and heated at 80 °C for 2 h. The reaction is cooled to rt and polymer supported EDC is added (33 mg, 3 meq/g, 0.5 mL slurry in DMF, 0.10 mmol, 5 equiv.) and the reaction is vortexed for 16 h. The product benzoxazine is filtered from the P-EDC and concentrated *in vacuo*. ¹H NMR (dms_o-d₆) 3.75 (s, 3), 6.95 (d, 2, *J* = 4), 7.20-7.40 (m, 2), 7.65 (d, 1, *J* = 4), 7.75 (dd, 1, *J* = 4,4), 7.95 (d, 1, *J* = 4). MS (*m/z*) 268.